US Food and Drug Administration officials emphasized the efficiency that its new Model-Integrated Evidence (MIE) pilot could create for generic drug sponsors in a bid to encourage participation.
The program will allow sponsors to meet with agency officials early in development to discuss potential quantitative methods and models for showing bioequivalence, potentially in lieu of clinical trials
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?